AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29617001 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (personalized based on ARR10 benefit threshold)
Number of subjects: 70
Study 29617001 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (personalized based on ARR10 benefit threshold ≥2.3%)
Number of subjects: 70
Study 29617210 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 772
Study 29617210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study 29617822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir maintenance monotherapy
Number of subjects: 10
Study 29618159 — intervention group
Group type: EXPERIMENTAL
Intervention: New generation P2Y12 inhibitors
Number of subjects: 1057
Study 29618159 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1057
Study 29618394 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-KP BSI
Number of subjects: 909
Study 29618394 — intervention group
Group type: COMPARATOR
Intervention: ESBL-EC BSI
Number of subjects: 909
Study 29618394 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX-M ESBL subtype
Number of subjects: 909
Study 29618479 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients treated on SWOG protocols
Number of subjects: 2361
Study 29618479 — intervention group
Group type: COMPARATOR
Intervention: Ineligible patients treated on SWOG protocols
Number of subjects: 2361
Study 29618495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 729
Study 29618660 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomics and random forest analysis
Number of subjects: 98
Study 29618660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rank regression
Number of subjects: 98
Study 29619534 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner-based, cluster-randomized controlled intervention trial (DelpHi-MV)
Number of subjects: 0
Study 29619534 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners and specialists identifying caregivers' unmet needs
Number of subjects: 0
Study 29619534 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet needs assessments for family caregivers of PwD
Number of subjects: 0
Study 29619634 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 grams daily
Number of subjects: 0
Study 29619634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29619656 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight status in PID patients
Number of subjects: 1167
Study 29619656 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight status in adults with CVID
Number of subjects: 1167
Study 29619656 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight status in pediatric CVID cohort
Number of subjects: 1167
Study 29619656 — intervention group
Group type: COMPARATOR
Intervention: Obesity in pediatric and adult PID patients
Number of subjects: 1167
Study 29619656 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of underweight status in PID
Number of subjects: 1167
Study 29619656 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of obesity in PID patients
Number of subjects: 1167
Study 29619769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (specifics not provided)
Number of subjects: 0
Study 29620391 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely access to mental health care
Number of subjects: 419
Study 29620391 — intervention group
Group type: COMPARATOR
Intervention: Medical appointments that interfere with other activities
Number of subjects: 419
Study 29620391 — intervention group
Group type: COMPARATOR
Intervention: Difficulty getting questions answered between visits
Number of subjects: 419
Study 29620391 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective ratings of VA care
Number of subjects: 419
Study 29620954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environment variables (high-fat food availability, low-fat food availability, food storage practices)
Number of subjects: 165
Study 29620954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environment variables
Number of subjects: 165
Study 29621615 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Tesla (7T)
Number of subjects: 62
Study 29621615 — intervention group
Group type: COMPARATOR
Intervention: 3 Tesla (3T)
Number of subjects: 62
Study 29621747 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (increased from 3.0 to 4.9 times per week)
Number of subjects: 332
Study 29622037 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM-760 30 mg once daily for 12 weeks
Number of subjects: 342
Study 29622037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 29622037 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM-760
Number of subjects: 342
Study 29622045 — intervention group
Group type: EXPERIMENTAL
Intervention: Connecting Latinos en Pareja (CLP)
Number of subjects: 0
Study 29622045 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman device
Number of subjects: 469
Study 29622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer device
Number of subjects: 469
Study 29622159 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 469
Study 29622159 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation at discharge
Number of subjects: 469
Study 29622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus on the device
Number of subjects: 469
Study 29622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular disease
Number of subjects: 469
Study 29622168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Ticagrelor
Number of subjects: 0
Study 29622168 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-Dose Ticagrelor
Number of subjects: 0
Study 29622168 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 29622288 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGFBP-7 in HFpEF
Number of subjects: 165
Study 29622288 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGFBP-7 in HFrEF
Number of subjects: 165
Study 29622527 — intervention group
Group type: EXPERIMENTAL
Intervention: Epic Allies app
Number of subjects: 146
Study 29622527 — intervention group
Group type: COMPARATOR
Intervention: Control condition (weekly phone-based notifications)
Number of subjects: 146
Study 29622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of intensive care
Number of subjects: 876
Study 29622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3 months, 6 months, and 1 year after ICU admission
Number of subjects: 876
Study 29622574 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual follow-up focusing on HRQoL, psychiatric symptoms, and healthcare utilisation
Number of subjects: 876
Study 29622656 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin and ifosfamide, carboplatin, etoposide
Number of subjects: 0
Study 29622755 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (xanthine oxidase inhibitor) for 6 months, lowering serum UA to <6 mg/dL
Number of subjects: 24
Study 29622755 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (xanthine oxidase inhibitor) for 6 months
Number of subjects: 24
Study 29623105 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (subtherapeutic concentrations)
Number of subjects: 210
Study 29623105 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (subtherapeutic concentrations)
Number of subjects: 210
Study 29623105 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (therapeutic concentrations)
Number of subjects: 210
Study 29623105 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (therapeutic concentrations)
Number of subjects: 210
Study 29623141 — intervention group
Group type: EXPERIMENTAL
Intervention: Gothic arch tracing method
Number of subjects: 0
Study 29623141 — intervention group
Group type: COMPARATOR
Intervention: Traditional method using wax occlusal rims
Number of subjects: 0
Study 29623470 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 4546
Study 29623470 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (implied control)
Number of subjects: 4546
Study 29623586 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma samples for EGFR mutation testing
Number of subjects: 154
Study 29623586 — intervention group
Group type: COMPARATOR
Intervention: Tumor tissue samples for EGFR mutation testing
Number of subjects: 154
Study 29623586 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between plasma and tumor samples
Number of subjects: 154
Study 29623932 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve-transfer (25 cases)
Number of subjects: 73
Study 29623932 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve-graft (19 cases)
Number of subjects: 73
Study 29623932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve (17 cases)
Number of subjects: 73
Study 29623932 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral C (not fully specified)
Number of subjects: 73
Study 29624409 — intervention group
Group type: EXPERIMENTAL
Intervention: SeptiCyte LAB
Number of subjects: 447
Study 29624558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 25
Study 29624558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg
Number of subjects: 25
Study 29624558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 1200 mg
Number of subjects: 25
Study 29624558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 800 mg every 8 hours × 3 doses (total dose 2400 mg)
Number of subjects: 25
Study 29624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood traumas (physical, sexual, emotional abuse and neglect)
Number of subjects: 1357
Study 29624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of each type of trauma
Number of subjects: 1357
Study 29624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of trauma
Number of subjects: 1357
Study 29624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall severity of childhood trauma
Number of subjects: 1357
Study 29624666 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dexterity (measured by Nine-Hole Peg Test and Box and Blocks Test)
Number of subjects: 60
Study 29624666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 60
Study 29624666 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dexterity
Number of subjects: 60
Study 29624876 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery thyroplasty (MTIS)
Number of subjects: 49
Study 29624882 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination coverage of 15.47%
Number of subjects: 8000
Study 29624882 — intervention group
Group type: COMPARATOR
Intervention: No vaccine coverage
Number of subjects: 8000
Study 29624882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital immunization program
Number of subjects: 8000
Study 29625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported irritability
Number of subjects: 197
Study 29625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 197
Study 29625571 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone self-management (ATSM) queries for diabetes, blood pressure, and cholesterol pills
Number of subjects: 210
Study 29625571 — intervention group
Group type: COMPARATOR
Intervention: Structured interview assessments
Number of subjects: 210
Study 29625571 — intervention group
Group type: EXPERIMENTAL
Intervention: ATSM adherence assessments
Number of subjects: 210
Study 29625579 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-matching to treatment options
Number of subjects: 400
Study 29625579 — intervention group
Group type: COMPARATOR
Intervention: Expert-matching to treatment options
Number of subjects: 400
Study 29625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (12 weeks of training including three 60-min sessions of aerobic exercise and resistance training, and two sessions of flexibility training per week)
Number of subjects: 28
Study 29625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 28
Study 29625622 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standard hospital treatment)
Number of subjects: 28
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) ≤2
Number of subjects: 333
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) 2.5-4
Number of subjects: 333
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Prognostic Index (PPI) >4
Number of subjects: 333
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 0-1
Number of subjects: 333
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 2
Number of subjects: 333
Study 29625809 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of Risk Factors (NRF) 3
Number of subjects: 333
Study 29625993 — intervention group
Group type: EXPERIMENTAL
Intervention: Video informed consent
Number of subjects: 7904
Study 29625993 — intervention group
Group type: COMPARATOR
Intervention: Text-based informed consent
Number of subjects: 7904
Study 29626135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of multiple burr hole procedure under local anesthesia and intravenous erythropoietin pretreatment
Number of subjects: 37
Study 29627083 — intervention group
Group type: EXPERIMENTAL
Intervention: 29-MHz, TRUS, micro-ultrasound system (ExactVu micro-ultrasound)
Number of subjects: 163
Study 29627083 — intervention group
Group type: COMPARATOR
Intervention: B-mode-based scoring and evaluation using the PRI-MUS protocol
Number of subjects: 163
Study 29627109 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 29627109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 29627147 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (10-50 million pfu)
Number of subjects: 217
Study 29627147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (300,000 pfu)
Number of subjects: 217
Study 29627147 — intervention group
Group type: COMPARATOR
Intervention: High dose vs Low dose
Number of subjects: 217
Study 29627147 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralising antibodies
Number of subjects: 217
Study 29627296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 3414
Study 29627296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3414
Study 29627309 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 1688
Study 29627309 — intervention group
Group type: COMPARATOR
Intervention: Comparator treatment
Number of subjects: 1688
Study 29627741 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 14
Study 29628014 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive candidiasis diagnosis
Number of subjects: 162
Study 29628014 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida score
Number of subjects: 162
Study 29628128 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (mild, ≥100 and <150 × 10^9/L)
Number of subjects: 19353
Study 29628128 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (severe, <100 × 10^9/L)
Number of subjects: 19353
Study 29628128 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal platelet counts)
Number of subjects: 19353
Study 29628312 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-803 (20 μg/kg subcutaneously once per week) in combination with nivolumab (240 mg intravenously every 14 days)
Number of subjects: 21
Study 29628368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 0
Study 29628368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29628397 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced labile plasma iron (eLPI) measured in serum samples with the FeROS eLPI kit; values greater than 0.4 μmol/L considered raised eLPI.
Number of subjects: 112
Study 29628397 — intervention group
Group type: EXPERIMENTAL
Intervention: eLPI as a biological mediator of iron-related toxicity.
Number of subjects: 112
Study 29628776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 11141
Study 29628776 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis
Number of subjects: 11141
Study 29628776 — intervention group
Group type: COMPARATOR
Intervention: Common mental disorders
Number of subjects: 11141
Study 29629179 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb motor competence (MC)
Number of subjects: 718
Study 29629179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb motor competence (MC)
Number of subjects: 718
Study 29629179 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and fitness measures
Number of subjects: 718
Study 29629190 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic awareness activities
Number of subjects: 4800
Study 29629190 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy indicators for detecting problematic antibiotic behaviours
Number of subjects: 4800
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Any medication taken during pregnancy
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Any medication taken in the first trimester
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (taking at least five medications)
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications taken during pregnancy (excluding vitamins, supplements, and vaccines)
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications taken in the first trimester (excluding vitamins, supplements, and vaccines)
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal or antiemetic agents
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 9546
Study 29630018 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 9546
Study 29630439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 165
Study 29630439 — intervention group
Group type: COMPARATOR
Intervention: Td
Number of subjects: 165
Study 29630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Women undergoing primary PCI
Number of subjects: 8834
Study 29630703 — intervention group
Group type: COMPARATOR
Intervention: Men undergoing primary PCI
Number of subjects: 8834
Study 29630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Women under 60 years
Number of subjects: 8834
Study 29630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 60 to 74 years
Number of subjects: 8834
Study 29630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Women over 75 years
Number of subjects: 8834
Study 29630703 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall relationship among sex, age category, and 30-day mortality after IPTW adjustment
Number of subjects: 8834
Study 29631575 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cotinine (n=4024)
Number of subjects: 4024
Study 29631575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (eCO) (n=2854)
Number of subjects: 4024
Study 29631575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes per day (CPD) (n=2706)
Number of subjects: 4024
Study 29631575 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation at year 5 follow-up (n=2892, 717 quitters and 2175 smokers)
Number of subjects: 4024
Study 29631584 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating sex hormones (testosterone, DHEA-S, estrogen, progesterone)
Number of subjects: 187
Study 29631615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cell (BMMSC) transplantation therapy
Number of subjects: 1
Study 29631615 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial therapy
Number of subjects: 1
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice (generalized)
Number of subjects: 1607
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice (intake-based)
Number of subjects: 1607
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice (intake+phenotype-based)
Number of subjects: 1607
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice (intake+phenotype+gene-based)
Number of subjects: 1607
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change techniques from dietary taxonomy
Number of subjects: 1607
Study 29631993 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change techniques from smoking cessation taxonomy
Number of subjects: 1607
Study 29631993 — intervention group
Group type: COMPARATOR
Intervention: Techniques excluded from the intervention
Number of subjects: 1607
Study 29632238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 23783
Study 29632238 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (Control)
Number of subjects: 23783
Study 29632238 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 23783
Study 29632238 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI (Glycoprotein IIb/IIIa inhibitor)
Number of subjects: 23783
Study 29632238 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events
Number of subjects: 23783
Study 29632533 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine administered in two doses (30 days apart)
Number of subjects: 20
Study 29632533 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine
Number of subjects: 20
Study 29632615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 961